North America Clinical Trials Market Forecast to 2028 - Regional Analysis - by Study Design, Phase, and Indication

The North America clinical trials market is expected to grow from US$ 27,322.28 million in 2022 to US$ 36,818.15 million by 2028. It is estimated to grow at a CAGR of 5.1% from 2022 to 2028.

Flourishing Pharmaceutical Industry and Increasing R&D Activities in Pharmaceutical Industry Fuels North America Clinical Trials Market

The pharmaceutical industry is one of the most R&D-intensive industries globally. The value of medicines is becoming increasingly important as pharmaceutical companies are keen to ensure that R&D achieves their intended goal. Over the last decade, the number of new drugs approved yearly has also increased. Efforts are being made to achieve greater effectiveness and efficiency in fulfilling patients' needs. The US is a leading country in R&D investments, producing over half of the world’s new molecules in the past decade. The US accounted for 62.3% of sales of new medicines launched during 2014-2019. R&D is a significant and essential part of the business of pharmaceutical companies as it enables them to come up with new molecules for various therapeutic applications with significant medical and commercial potential.

R&D expenditure is done to discover, examine, and produce new products; upfront payments; improve existing outcomes; and demonstrate product efficacy and regulatory compliance before launch. The R&D investments differ as per the need and demand for clinical trials. The cost includes materials, supplies used, and salaries, along with the cost of developing quality control.

North America Clinical Trials Market Overview

The North America clinical trials market is segmented into the US, Canada, and Mexico. The US is the largest and fastest-growing market for clinical trials. The market growth in the region is accredited to the US emerging as a leading clinical research destination and the innovative services offered by companies for applications in clinical trials.

The US has emerged as a leading clinical research destination. Nearly half of the total clinical trials are conducted in the US. Additionally, most pharma research companies prefer to perform clinical trials in the US owing to established medical infrastructure, fast approval timelines, a favorable regulatory framework, and accepted clinical trial generated data globally. A World Health Organization (WHO) report states that the US registered the highest number of clinical trials (157,618) in 2021.

North America clinical Trials Market Revenue and Forecast to 2028 (US$ Million)

North America Clinical Trials Market Segmentation

The North America clinical trials market is segmented into phase, study design, indication, and country.

Based on phase, the North America clinical trials market is segmented into phase I, phase II, phase III, and phase IV. The phase III segment registered the largest North America clinical trials market share in 2022.

Based on study design, the North America clinical trials market is segmented into interventional, observational, and expanded access. The interventional segment held the largest North America clinical trials market share in 2022.

Based on Indication, the North America clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular, and others. The oncology segment held the largest North America clinical trials market share in 2022.

Based on country, the North America clinical trials market has been categorized into the US, Canada, and Mexico. The US dominated the North America clinical trials market share in 2022.

Charles River Laboratories International Inc, ICON Plc, IQVIA Holdings Inc, IXICO Plc, Laboratory Corp of America Holdings, Parexel International Corp, SGS SA, Syneos Health Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd. are some of the leading companies operating in the North America clinical trials market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America clinical trials market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the North America clinical trials market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth North America market trends and outlook coupled with the factors driving the clinical trials market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution